FDA Commissioner nominee Marty Makary (Noam Galai/Getty Images for HBO)
November 25, 2024 04:12 PM ESTUpdated 04:39 PM
R&D

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Max Bayer

Pharma Reporter

Now that Pres­i­dent-elect Don­ald Trump has made his choice for FDA com­mis­sion­er, re­ac­tions and analy­sis are pour­ing in from bio­phar­ma ex­ec­u­tives and for­mer staffers who …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

A service from the Financial Times